Separate medical products from general-use claims
Brazil's current official sources describe regulated medicinal products, research, and licensed cultivation. These are separate from a general consumer permission. A product authorization or industry license should not be read as a blanket adult-use rule.
What changed in Anvisa's 2026 rules
Anvisa says RDC 1.015/2026 updated the authorization framework for human medicinal cannabis products and took effect on May 4, 2026. The agency also describes separate rules for cultivation and research. Check the current Anvisa Q&A and underlying regulations for product status, forms, and deadlines; an agency authorization does not mean every product is registered or approved.
Cultivation and research have separate gates
Anvisa's current cultivation page says the rules cover research and defined medical or pharmaceutical activity. It describes special authorization, prior checks, controls, and distinct routes based on purpose and THC profile. The agency says only activities expressly allowed under the applicable rules may proceed. This is a regulated institutional pathway, not home-cultivation or personal-use advice.
What remains outside this summary
The STF's Tema 506 page was discoverable in official search results but failed direct open in this check. Because the exact judgment could not be directly reviewed, this guide does not repeat a personal-possession threshold or state that the decision creates general permission. Compare Colombia's regulated framework for another South American official-source guide.
Quick FAQ
Did Brazil's 2026 Anvisa rules legalize general adult-use cannabis?
No. The cited rules cover medicinal products, research, and specifically authorized cultivation; they do not establish general adult-use permission.
When did RDC 1.015/2026 take effect?
Anvisa says the updated product authorization framework entered into force on May 4, 2026.
Does this page state the amount allowed for personal possession?
No. The STF page was access-limited during this check. This guide gives no numeric personal-possession threshold; check the current decision and local implementation.
Sources
- Anvisa: 2026 medicinal cannabis production rules -- directly read 2026-09-25.
- Anvisa: RDC 1.012/2026 and 1.013/2026 -- directly read 2026-09-25; these cover cultivation/research, not the separate product-rule effective date.
- Anvisa RDC 1.015/2026, Article 77 -- directly opened primary text; Article 77 sets this separate medicinal-product rule's effective date as May 4, 2026.
- STF Tema 506 -- official search result only; direct open failed, so no personal-possession threshold is asserted.
Confirm current statutes and case implementation before relying on any Brazil-wide personal-use summary.